Encyclopedia of Nanotechnology

Living Edition
| Editors: Bharat Bhushan

Nanotechnology in Pulmonary Disease

  • James C. Bonner
Living reference work entry
DOI: https://doi.org/10.1007/978-94-007-6178-0_100904-1


Nanotechnology in pulmonary disease encompasses the potential human health risks from occupational, environmental, or consumer exposure to engineered nanomaterials as well as the therapeutic benefits of nanomaterials for drug delivery to treat pulmonary diseases, enhance medical imaging of lung diseases, or provide tissue engineering for regenerative medicine.


Engineered nanomaterials (ENMs) are intentionally manufactured nanoparticles with at least one dimension <100 nm that can be mass produced with a high degree of conformity in size and shape. The risk of ENMs to human health, specifically pulmonary disease, is not yet known due to the relative infancy of the nanotechnology revolution. However, studies with rodents that show adverse pro-inflammatory, pro-fibrogenic, and carcinogenic effects suggest that at least some ENMs will pose a human health hazard. Also, the utility of ENMs for therapies aimed at the treatment of pulmonary diseases in an early stage of...


Chronic Obstructive Pulmonary Disease Pulmonary Fibrosis Solid Lipid Nanoparticles Allergic Airway Inflammation Super Paramagnetic Iron Oxide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. 1.
    Bonner, J.C.: Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair 3, 15 (2010)CrossRefGoogle Scholar
  2. 2.
    Donaldson, K., Murphy, F., Schinwald, A., Duffin, R., Poland, C.A.: Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine (Lond.) 6(1), 143–156 (2011)CrossRefGoogle Scholar
  3. 3.
    Kelleher, P., Pacheco, K., Newman, L.S.: Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ. Health Perspect. 108(Suppl 4), 685–696 (2000)CrossRefGoogle Scholar
  4. 4.
    Bonner, J.C.: Respiratory toxicity. In: Smart, R.C., Hodgson, E. (eds.) Molecular and Biochemical Toxicology, 4th edn, pp. 639–670. Wiley, Hoboken (2008)CrossRefGoogle Scholar
  5. 5.
    Thompson, E.A., Sayers, B.C., Glista-Baker, E.E., Shipkowski, K.A., Taylor, A.J., Bonner, J.C.: Innate immune responses to nanoparticle exposure in the lung. J. Environ. Immunol. Toxicol. 1(3), 150–156 (2013)Google Scholar
  6. 6.
    Ryman-Rasmussen, J.P., Andersen, M.E., Bonner, J.C.: Fate and effects of carbon nanotubes following inhalation. In: Donaldson, K., Poland, C.A., Duffin, R., Bonner, J. (eds.) The Toxicology of Carbon Nanotubes, pp. 118–133. Cambridge University Press, Cambridge (2012)Google Scholar
  7. 7.
    Glista-Baker, E.E., Taylor, A.J., Sayers, B.C., Thompson, E.A., Bonner, J.C.: Nickel nanoparticles cause exaggerated lung and airway remodeling in mice lacking the T-box transcription factor, TBX21 (T-bet). Part. Fibre Toxicol. 11, 7 (2014)CrossRefGoogle Scholar
  8. 8.
    Schins, R.P.F., Albrecht, C., Gerloff, K.: Genotoxicity of carbon nanotubes. In: Donaldson, K., Poland, C.A., Duffin, R., Bonner, J. (eds.) The Toxicology of Carbon Nanotubes, pp. 150–173. Cambridge University Press, Cambridge (2012)Google Scholar
  9. 9.
    Sargent, L.M., Reynolds, S.H., Castranova, V.: Potential pulmonary effects of engineered carbon nanotubes: in vitro genotoxic effects. Nanotoxicology 4, 396–408 (2010)CrossRefGoogle Scholar
  10. 10.
    De Jong, W.H., Borm, P.H.: Drug delivery and nanoparticles: applications and hazards. Int. J. Nanomedicine 3(2), 133–149 (2008)CrossRefGoogle Scholar
  11. 11.
    Thorley, A.J., Tetley, T.D.: New perspectives in nanomedicine. Pharmacol. Ther. 140(2), 176–185 (2013)CrossRefGoogle Scholar
  12. 12.
    Vij, N., Gorde, A.: Theranostic applications of nanotechnology in chronic obstructive lung diseases. In: Vij, N. (ed.) Pulmonary Nanomedicine: Diagnostics, Imaging, and Therapeutics, pp. 1–14. Pan Stanford Publishing, Boca Raton (2012)CrossRefGoogle Scholar
  13. 13.
    Prato, M., Kostarelos, K., Bianco, A.: Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 41(1), 60–68 (2008)CrossRefGoogle Scholar
  14. 14.
    Bonner, J.C.: Carbon nanotubes as delivery systems for respiratory disease: do the dangers outweigh the potential benefits? Expert Rev. Respir. Med. 5(6), 779–787 (2011)CrossRefGoogle Scholar
  15. 15.
    Hirsch, C., Roesslein, M., Krug, H.F., Wick, P.: Nanomaterial cell interactions: are current in vitro tests reliable? Nanomedicine (Lond.) 6(5), 837–847 (2011)CrossRefGoogle Scholar
  16. 16.
    Kreyling, W.G., Hirn, S., Schleh, C.: Nanoparticles in the lung. Nat. Biotechnol. 28(12), 1275–1276 (2010)CrossRefGoogle Scholar
  17. 17.
    Chandolu, V., Dass, C.R.: Treatment of lung cancer using nanoparticle drug delivery systems. Curr. Drug Discov. Technol. 10(2), 170–176 (2013)CrossRefGoogle Scholar
  18. 18.
    Kuroda, S., Yokoyama, T., Tam, J.O., Scott, A.W., Ma, L.L., Shanker, M., Jin, J., Goerlich, C., Willcutts, D., Roth, J.A., Sokolov, K., Johnston, K.P., Ramesh, R.: Multifunctional tumor-targeted nanoparticles for lung cancer. In: Vij, N. (ed.) Pulmonary Nanomedicine: Diagnostics, Imaging, and Therapeutics, pp. 15–44. Pan Stanford Publishing, Boca Raton (2012)CrossRefGoogle Scholar
  19. 19.
    Mulvey, J.J., Villa, C.H., McDevitt, M.R., Escorcia, F.E., Casey, E., Scheinberg, D.A.: Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nat. Nanotechnol. 8(10), 763–771 (2013)CrossRefGoogle Scholar
  20. 20.
    Chakravarty, P., Marches, R., Zimmerman, N.S., Swafford, A.D., Bajaj, P., Musselman, I.H., Pantano, P., Draper, R.K., Vitteta, P.S.: Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc. Natl. Acad. Sci. U. S. A. 105(25), 8697–8702 (2008)CrossRefGoogle Scholar
  21. 21.
    Mehanna, M.M., Mohyeldin, S.M., Elgindy, N.A.: Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J. Control. Release 187C, 183–197 (2014)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of Biological SciencesNorth Carolina State UniversityRaleighUSA